Table 2. SNV/CNA tracking in nine metastatic breast cancer patients by NGS.

Patient ID	Study Sample (months)	Age	ER	PR	Her2	CA15-3 (U/ml)	cfDNA genomic copies/ml	SNV (AA mutation) and VAF				COSMIC ID	Gene amplification
Patient ID	Study Sample (months)	Age	ER	PR	Her2	CA15-3 (U/ml)	cfDNA genomic copies/ml	Gene	Mutation	VAF (%)	Coverage	COSMIC ID	Gene amplification
1	Baseline	52	pos	pos	pos	602	2,076	PIK3CA	p.H1047R	7.8	1988	COSM775	NOMO2 and ERBB2
1	5	52	pos	pos	pos	376	2,727	PIK3CA	p.H1047R	4.9	1100	COSM775	ERBB2
2	Baseline	45	pos	pos	neg	25	4,697	PIK3CA TP53	p.H1047R p.R248Q	2.5 6.5	1260 876	COSM775 COSM10662	ERBB2
2	20	45	pos	pos	neg	131	5,515						-
3	Baseline	74	pos	pos	neg	29	3,545	PIK3CA	p.H1047R	5	2145	COSM775	-
3	14	74	pos	pos	neg	24	5,742		-				-
4	Baseline	80	pos	pos	neg	150	13,041	PIK3CA ESR1	p.N345K p.Y537N	11.7 10.9	1357 457	COSM36200 COSM1074635	-
4	2	80	pos	pos	neg	194	3,655	PIK3CA ESR1	p.N345K p.Y537N	1 0.5	1660 528	COSM754 COSM1074635	-
5	Baseline	49	pos	pos	pos	23	12,621						-
5	2	49	pos	pos	pos	23	13,970						-
6	Baseline	27	pos	pos	neg	23	4,455						-
	11					23	9,212						-
	17					25	2,115	PIK3CA	p.H1047R	1	1181	COSM775	-
	24					56	7,318	PIK3CA TP53	p.H1047R p.E271G	10.1 6.2	1738 64	COSM775 COSM43879	-
7	Baseline	72	pos	NA	neg	314	6,409		-				-
7	1	72	pos	NA	neg	395	31,364	LMTK3	p.E1251V	3.5	1995		-
8	Baseline	51	pos	pos	neg	20	1,515						-
	7					46	2,621						-
	9					221	4,864						-
	10					567	11,727						ERBB2 and MYC
	13					252	9,818						-
9	Baseline	43	pos	pos	neg	74	2,197		-				-
	3					110	4,803		-				-
	6					168	504,545	PIK3CA ESR1	p.E545K p.D538G	17.8 28.6	1159 353	COSM763 COSM94250	CCND1
	12					147	96,970		-				-
	13					138	86,667		-				-

Age is the age at the time of the first blood sample.